Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
about
Syk inhibitors in clinical development for hematological malignancies.Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma
P2860
Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Inhibition of BCR signaling us ...... ic lymphocytic leukemia cells.
@en
Inhibition of BCR signaling us ...... ic lymphocytic leukemia cells.
@nl
type
label
Inhibition of BCR signaling us ...... ic lymphocytic leukemia cells.
@en
Inhibition of BCR signaling us ...... ic lymphocytic leukemia cells.
@nl
prefLabel
Inhibition of BCR signaling us ...... ic lymphocytic leukemia cells.
@en
Inhibition of BCR signaling us ...... ic lymphocytic leukemia cells.
@nl
P2093
P2860
P356
P1433
P1476
Inhibition of BCR signaling us ...... ic lymphocytic leukemia cells.
@en
P2093
Carles Palacio
Cecilia Carpio
Júlia Carabia
Leire Egia
Meritxell Aguiló
Noelia Purroy
Pau Abrisqueta
P2860
P304
P356
10.18632/ONCOTARGET.13557
P407
P577
2016-11-24T00:00:00Z